Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets
Aberrant metabolism is a major hallmark of cancer. Abnormal cancer metabolism, such as aerobic glycolysis and increased anabolic pathways, has important roles in tumorigenesis, metastasis, drug resistance, and cancer stem cells. Well-known oncogenic signaling pathways, such as phosphoinositide 3-kin...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/9/10/2308 |
| _version_ | 1797550719959564288 |
|---|---|
| author | Jae Hyung Park Woo Yang Pyun Hyun Woo Park |
| author_facet | Jae Hyung Park Woo Yang Pyun Hyun Woo Park |
| author_sort | Jae Hyung Park |
| collection | DOAJ |
| description | Aberrant metabolism is a major hallmark of cancer. Abnormal cancer metabolism, such as aerobic glycolysis and increased anabolic pathways, has important roles in tumorigenesis, metastasis, drug resistance, and cancer stem cells. Well-known oncogenic signaling pathways, such as phosphoinositide 3-kinase (PI3K)/AKT, Myc, and Hippo pathway, mediate metabolic gene expression and increase metabolic enzyme activities. Vice versa, deregulated metabolic pathways contribute to defects in cellular signal transduction pathways, which in turn provide energy, building blocks, and redox potentials for unrestrained cancer cell proliferation. Studies and clinical trials are being performed that focus on the inhibition of metabolic enzymes by small molecules or dietary interventions (e.g., fasting, calorie restriction, and intermittent fasting). Similar to genetic heterogeneity, the metabolic phenotypes of cancers are highly heterogeneous. This heterogeneity results from diverse cues in the tumor microenvironment and genetic mutations. Hence, overcoming metabolic plasticity is an important goal of modern cancer therapeutics. This review highlights recent findings on the metabolic phenotypes of cancer and elucidates the interactions between signal transduction pathways and metabolic pathways. We also provide novel rationales for designing the next-generation cancer metabolism drugs. |
| first_indexed | 2024-03-10T15:33:19Z |
| format | Article |
| id | doaj.art-3dbc14261ff145c2a6d106547c1a17f0 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T15:33:19Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-3dbc14261ff145c2a6d106547c1a17f02023-11-20T17:26:27ZengMDPI AGCells2073-44092020-10-01910230810.3390/cells9102308Cancer Metabolism: Phenotype, Signaling and Therapeutic TargetsJae Hyung Park0Woo Yang Pyun1Hyun Woo Park2Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, KoreaDepartment of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, KoreaDepartment of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, KoreaAberrant metabolism is a major hallmark of cancer. Abnormal cancer metabolism, such as aerobic glycolysis and increased anabolic pathways, has important roles in tumorigenesis, metastasis, drug resistance, and cancer stem cells. Well-known oncogenic signaling pathways, such as phosphoinositide 3-kinase (PI3K)/AKT, Myc, and Hippo pathway, mediate metabolic gene expression and increase metabolic enzyme activities. Vice versa, deregulated metabolic pathways contribute to defects in cellular signal transduction pathways, which in turn provide energy, building blocks, and redox potentials for unrestrained cancer cell proliferation. Studies and clinical trials are being performed that focus on the inhibition of metabolic enzymes by small molecules or dietary interventions (e.g., fasting, calorie restriction, and intermittent fasting). Similar to genetic heterogeneity, the metabolic phenotypes of cancers are highly heterogeneous. This heterogeneity results from diverse cues in the tumor microenvironment and genetic mutations. Hence, overcoming metabolic plasticity is an important goal of modern cancer therapeutics. This review highlights recent findings on the metabolic phenotypes of cancer and elucidates the interactions between signal transduction pathways and metabolic pathways. We also provide novel rationales for designing the next-generation cancer metabolism drugs.https://www.mdpi.com/2073-4409/9/10/2308cancer metabolismcell signalingdrug developmentmetabolic plasticity |
| spellingShingle | Jae Hyung Park Woo Yang Pyun Hyun Woo Park Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets Cells cancer metabolism cell signaling drug development metabolic plasticity |
| title | Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets |
| title_full | Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets |
| title_fullStr | Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets |
| title_full_unstemmed | Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets |
| title_short | Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets |
| title_sort | cancer metabolism phenotype signaling and therapeutic targets |
| topic | cancer metabolism cell signaling drug development metabolic plasticity |
| url | https://www.mdpi.com/2073-4409/9/10/2308 |
| work_keys_str_mv | AT jaehyungpark cancermetabolismphenotypesignalingandtherapeutictargets AT wooyangpyun cancermetabolismphenotypesignalingandtherapeutictargets AT hyunwoopark cancermetabolismphenotypesignalingandtherapeutictargets |